Education
About Us
Working with TipRanks
Follow Us
Taysha Gene Therapies (TSHA)
NASDAQ:TSHA
Total Valuation
Taysha Gene Therapies has a market cap or net worth of $365.00M. The enterprise value is $279.02M.
Market Cap$365.00M
Enterprise Value$279.02M
Share Statistics
Taysha Gene Therapies has 205,054,570 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding205,054,570
Owned by Insiders16.18%
Owned by Institutions<0.01%
Financial Efficiency
Taysha Gene Therapies’s return on equity (ROE) is -1.25 and return on invested capital (ROIC) is -68.18%.
Return on Equity (ROE)-1.25
Return on Assets (ROA)-0.56
Return on Invested Capital (ROIC)-68.18%
Return on Capital Employed (ROCE)-0.68
Revenue Per Employee114.15K
Profits Per Employee-1.22M
Employee Count73
Asset Turnover0.05
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Taysha Gene Therapies is -4.85. Taysha Gene Therapies’s PEG ratio is 0.08.
PE Ratio-4.85
PS Ratio40.35
PB Ratio6.05
Price to Fair Value6.05
Price to FCF-5.30
Price to Operating Cash Flow-5.33
PEG Ratio0.08
Income Statement
In the last 12 months, Taysha Gene Therapies had revenue of 8.33M and earned -89.30M in profits. Earnings per share was -0.36.
Revenue8.33M
Gross Profit8.33M
Operating Income-91.46M
Pretax Income-89.30M
Net Income-89.30M
EBITDA-87.95M
Earnings Per Share (EPS)-0.36
Cash Flow
In the last 12 months, operating cash flow was -81.24M and capital expenditures -374.00K, giving a free cash flow of -81.62M billion.
Operating Cash Flow-81.24M
Free Cash Flow-81.62M
Free Cash Flow per Share-0.40
Dividends & Yields
Taysha Gene Therapies pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.33
52-Week Price Change-20.87%
50-Day Moving Average1.57
200-Day Moving Average1.93
Relative Strength Index (RSI)64.51
Average Volume (3m)2.32M
Important Dates
Taysha Gene Therapies upcoming earnings date is May 7, 2025, TBA Not Confirmed.
Last Earnings DateFeb 26, 2025
Next Earnings DateMay 7, 2025
Ex-Dividend Date―
Financial Position
Taysha Gene Therapies as a current ratio of 5.42, with Debt / Equity ratio of 88.33%
Current Ratio5.42
Quick Ratio5.42
Debt to Market Cap0.04
Net Debt to EBITDA1.38
Interest Coverage Ratio-896.66
Taxes
In the past 12 months, Taysha Gene Therapies has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Taysha Gene Therapies EV to EBITDA ratio is -3.54, with an EV/FCF ratio of -3.81.
EV to Sales37.33
EV to EBITDA-3.54
EV to Free Cash Flow-3.81
EV to Operating Cash Flow-3.83
Balance Sheet
Taysha Gene Therapies has $139.04M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$75.86M billion.
Cash & Marketable Securities$139.04M
Total Debt$0.00
Net Cash-$75.86M
Net Cash Per Share-$0.37
Tangible Book Value Per Share$0.29
Margins
Gross margin is 100.00%, with operating margin of -1097.55%, and net profit margin of -1071.62%.
Gross Margin100.00%
Operating Margin-1097.55%
Pretax Margin-1071.62%
Net Profit Margin-1071.62%
EBITDA Margin-1055.45%
EBIT Margin-1070.39%
Analyst Forecast
The average price target for Taysha Gene Therapies is $6.63, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$6.63
Price Target Upside264.29% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast-46.07%
EPS Growth Forecast71.52%